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Perfused myocardiumGlucose uptake from the bloodstream is the rate-limiting step in whole body glucose utilization, and is reg-
ulated by a family of membrane proteins called glucose transporters (GLUTs). Although GLUT4 is the pre-
dominant isoform in insulin-sensitive tissues, there is recent evidence that GLUT12 could be a novel
second insulin-sensitive GLUT. However, its physiological role in the heart is not elucidated and the regula-
tion of insulin-stimulated myocardial GLUT12 translocation is unknown. In addition, the role of GLUT12
has not been investigated in the diabetic myocardium. Thus, we hypothesized that, as for GLUT4, insulin reg-
ulates GLUT12 translocation to the myocardial cell surface, which is impaired during diabetes. Active cell sur-
face GLUT (-4 and -12) content was quantiﬁed (before and after insulin stimulation) by a biotinylated
photolabeled assay in both intact perfused myocardium and isolated cardiac myocytes of healthy and type
1 diabetic rodents. GLUT localization was conﬁrmed by immunoﬂuorescent confocal microscopy, and total
GLUT protein expression was measured by Western blotting. Insulin stimulation increased translocation of
GLUT-4, but not -12, in the healthy myocardium. Total GLUT4 content of the heart was decreased during di-
abetes, while there was no difference in total GLUT12. Active cell surface GLUT12 content was increased in
the diabetic myocardium, potentially as a compensatory mechanism for the observed downregulation of
GLUT4. Collectively, our data suggest that, in contrast to GLUT4, insulin does not mediate GLUT12 transloca-
tion, which may function as a basal GLUT located primarily at the cell surface in the myocardium.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The heart is one of the main organs to utilize glucose as an energy
substrate in order to provide a constant ATP supply to support the
high rate of cardiac power. Glucose transport and utilization by cardi-
ac myocytes is critical for maintenance of cardiac function. As a con-
sequence, diabetes, which is characterized by dysfunctional glucose
uptake into striated muscles, leads to major impairments in both
myocardial metabolism and function [1–3]. Glucose uptake from the
bloodstream is the rate-limiting step in whole body glucose utiliza-
tion, and is regulated by a family of membrane proteins called glucose
transporters (GLUTs). The well-established GLUT4 is the predominant
isoform in the heart and provides the majority of insulin-stimulated
glucose uptake by a translocation process from an intracellular (non
active) pool to the plasma membrane (active site). Although it has
been thought that GLUT4 translocation is the rate-limiting step foretes; Con, control; L, labeled;
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rights reserved.glucose uptake and utilization [4], GLUT4 knockoutmice do not devel-
op hyperglycemia, suggesting that other GLUT isoforms may also be
involved in the regulation of whole body glucose homeostasis [5]. In-
deed, thirteen other isoforms have been identiﬁed, and divided into 3
different classes based on their distinct regulatory and/or kinetic
properties that reﬂect their speciﬁc roles in cellular and whole body
glucose homeostasis [6]. Importantly, there is recent evidence that
GLUT12 (member of Class III) could be a novel second insulin-
sensitive GLUT in skeletal muscle [7,8]. Furthermore, GLUT12 mRNA
is highly expressed in adult human hearts [9] and GLUT12 protein is
present in signiﬁcant quantities in insulin-sensitive tissue, including
the heart [10]. Clearly, the potentially key role for GLUT12 in the reg-
ulation of myocardial glucose homeostasis warrants timely investiga-
tion. However, insulin stimulation of GLUT12 translocation has not
been investigated in the heart and its contribution to normal cardiac
glucose transport is unknown. Furthermore, while a recent study has
demonstrated a signiﬁcant role for GLUT12 in regulating whole body
insulin sensitivity [8], its function in the pathogenesis of insulin resis-
tance and diabetes has not been well established, and the role of
GLUT12 in the diabetic myocardium has not been studied. Better un-
derstanding of the role of this most recently identiﬁed GLUT isoform
could provide novel insights into the regulation of myocardial glucose
transport during physiological and pathological conditions, which
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Therefore, we hypothesized that, as for GLUT4, insulin regulates
GLUT12 translocation to the cell surface in the healthy myocardium,
which is impaired during diabetes.
2. Methods
2.1. Animals
Healthy and insulin-deﬁcient diabetic (Dx) FVB/Nmice were used.
Type 1 diabetes was induced at 12–16 weeks of age by 3 consecutive
streptozotocin injections (65–95 mg/kg IP every 48 h). The control
group received similar volume of vehicle. Venous blood was drawn
weekly from the facial vein for measurement of glucose, using a
glucometer (Bayer Contour, Tarrytown, NY) on mice previously
fasted overnight for 12 h. In vitro experiments were performed at
8 weeks after the induction of diabetes or in age-matched healthy
controls, 24–48 h after the ﬁnal blood [glucose] sample was taken.
All procedures were approved by the Ohio State University Institu-
tional Animal Care and Use Committee.
2.2. Western immunoblotting
Crude extracts of membrane-enriched ventricular myocardium or
gastrocnemius skeletal muscle were prepared as previously described
[10–13]. Brieﬂy, frozen tissue samples were homogenized in buffer,
which contains (mM): sucrose 210, NaCl 40, EDTA 2, HEPES 30, and
protease inhibitor (Sigma, St. Louis, MO). The homogenate was incu-
bated with sodium pyrophosphate 58 mM and KCl 1.17 mM. Crude
membranes were then recovered by centrifugation at 100,000 g for
90 min at 4 °C. Pellets were resuspended with a solution containing
(mM): Tris·HCl 10, and EDTA 1. After addition of SDS (16%, 0.33
total volume), samples were centrifuged at 3000 g for 25 min, and
the supernatant was stored at −80 °C until Western blot analysis.
Extracts were subsequently resolved by sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) electrophoresis, electrophoretically
transferred to PVDF membranes, and subjected to immunoblotting
[10–13]. Membrane proteins were incubated with rabbit polyclonal
antibodies against human GLUT4 (1:7500, AbD Serotec, Raleigh, NC)
or against rat GLUT12 (1:500, Abcam, Cambridge, MA). Primary anti-
bodies were chosen based on their 100% sequence homology with the
protein in mice, and validated against a positive control. Subsequent-
ly, the membrane was incubated with secondary antibody conjugat-
ed to horseradish peroxidase (GE Healthcare, Buckinghamshire,
UK). Quantitative determination of protein was performed by autora-
diography after revealing the antibody-bound protein by enhanced
chemiluminescence reaction. Equal protein loading was conﬁrmed by
reprobing each membrane for calsequestrin protein expression
(1:2500, Millipore, Billerica, MA).
2.3. GLUT translocation to the cell surface
Isolated hearts underwent a 30-min baseline Langendorff perfu-
sion followed by 35 min of additional perfusion with or without insu-
lin (at physiologic concentration, 100 μU/ml) before photolabeling
with the cell surface impermeant biotinylated bis-mannose reagent
(bio-LC-ATB-BGPA, 300 μM), of which the hexose group interacts
speciﬁcally with the extracellular binding site of GLUT [14,15]. The
photolabeled reagent was infused through the aorta and photochem-
ically cross-linked to cell surface GLUTs using a Rayonet photochem-
ical reactor (340 nm, Southern New England UV). The heart was then
ﬂash-frozen in liquid nitrogen and stored at−80° until further anal-
ysis. Total cardiac membrane extracts of photolabeled myocardial tis-
sue (“total lysate” fraction) were incubated with streptavidin bound
to 6% agarose beads (Pierce, Rockford, IL), which allows separation
of non-cell surface GLUTs (“unlabeled” or intracellular fraction) thatremain in the supernatant from cell surface GLUTs (“labeled” or sar-
colemmal fraction) [11,15]. All fractions were then subjected to
SDS-PAGE and subsequent immunoblotting with GLUT-4 or -12 anti-
body as described above. In a separate set of experiments, cardiac
myocytes were isolated by perfusion in a retrograde manner using a
Langendorff apparatus [16], and then incubated for 20 min without
(basal) or with insulin (100 μU/ml). Bio-LC-ATB-BGPA photolabeled
compound was then added to the incubation media and cross-
linked to cell surface GLUTs after 1 min. The cells were then washed
with Tyrode, solubilized in lysis buffer, and subjected to protein quan-
tiﬁcation and Western blotting as described above.
2.4. Immunoﬂuorescent confocal microscopy
The effect of insulin on the subcellular distribution of GLUT4 and
GLUT12 was examined by confocal laser scanning microscopy, as de-
scribed previously [17]. In brief, cardiac myocytes were incubated
without or with insulin (100 μU/ml) for 30 min prior to immunoﬂu-
orescent staining. Cells were ﬁxed with 4% formaldehyde in PBS for
30 min, blocked, permeabilized in 5% goat serum in PBS with 0.1% Tri-
ton X-100 (30 min), and labeled with primary antibody for overnight.
Cells were then washed three times and labeled with ﬂuorescence-
conjugated secondary antibody for 1 h. Immunoﬂuorescence was
visualized with confocal laser scanning microscopy (Olympus FV
1000). All images were analyzed ofﬂine.
2.5. Statistics
Differences between means were assessed by paired t-test,
Student's t-test or ANOVA, as appropriate (Sigmastat, Jandel Scientiﬁc).
When a signiﬁcant difference was identiﬁed by ANOVA, post hoc
tests were performed using the Student–Newman–Keuls technique.
Statistical signiﬁcance was deﬁned as Pb0.05. Data are presented
as mean±SE.
3. Results
3.1. Basal cardiac GLUT regulation
Since the regulation of GLUT12 in the heart has not been investi-
gated in healthy and diabetic state, we ﬁrst measured GLUT protein
expression from a crude membrane-enriched fraction in cardiac mus-
cle. Compared to healthy state, cardiac crude membrane GLUT4 con-
tent was decreased in the diabetic heart, while there was no change
in crude membrane GLUT12 (Fig. 1). By contrast, insulin-dependent
diabetes resulted in a signiﬁcant increase in GLUT12 protein content
in skeletal muscle (Fig. 1S). However, it is important to note that
the crude membrane extract contains total cellular membranes, and
thus active plasma membrane-associated GLUTs cannot be accurately
differentiated from inactive GLUTs that are associated with intracellu-
lar membranes or that have not yet fused with the plasma membrane
[15]. Therefore, we used a biotinylation assay in the intact perfused
heart to reliably and speciﬁcally quantify the proportion of active
GLUT at the myocardial cell surface (Fig. 2). As expected, diabetes de-
creased basal active cell surface GLUT4 content; by contrast, basal cell
surface GLUT12 content was increased during diabetes (Fig. 2A). Fur-
thermore, we quantiﬁed the proportion of GLUT located at the myo-
cardial cell surface compared to intracellularly for both GLUT-4 and
-12 in the photolabeled myocardium. As expected, under basal condi-
tion, the amount of GLUT4 at the cell surface was 31.1±6.1 and
18.6±6.77% of total myocardial GLUT4 protein in healthy and diabet-
ic myocardium, respectively (Fig. 2B). By contrast, basal cell surface
GLUT12 content contributed to the majority of myocardial GLUT12
protein, such that it was 64.4±17.3 and 63.2±9.04% of total myocar-
dial GLUT12 protein in healthy and diabetic myocardium, respectively
(Fig. 2C).
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Fig. 2. A) Diabetes increases active cell surface GLUT12 in photolabeled intact perfused
myocardium. Isolated perfused hearts from healthy (Con) and type 1 diabetic (Dx)
mice were photolabeled with bio-LC-ATB-BGPA to determine the amount of cell sur-
face (L: labeled fraction) and intracellular (UL: unlabeled fraction) content. Top
panel: Representative Western Blot. Bottom panel: Mean±SE GLUT protein content
under basal conditions (expressed relative to internal control; n=7–10/group). B)
While GLUT4 is primarily located intracellularly, C) the majority of GLUT12 protein is
active at the cell surface. Method: Isolated perfused hearts from healthy (Con) and
type 1 diabetic (Dx) mice were photolabeled with bio-LC-ATB-BGPA to determine
the amount of cell surface (L: labeled fraction) and intracellular (UL: unlabeled frac-
tion) content. *Pb0.05 vs. Con, †Pb0.05 vs. labeled fraction.
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Fig. 1. In a crude membrane-enriched fraction, insulin-dependent diabetes results in
no change in cardiac GLUT12 protein content, despite decreased cardiac GLUT4. Top
panel: Western blot of cardiac muscle from healthy (Con) and type 1 diabetic (Dx)
mice. Total calsequestrin (CASQ) protein content was used as a loading control. Bottom
panel: Mean±SE total GLUT protein content in a crude membrane-enriched fraction,
(n=5–10/group), *Pb0.05 vs. control group.
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We then investigated whether as for GLUT4, cardiac GLUT12 is
regulated by insulin stimulation using the biotinylation assay in
healthy cardiac myocytes incubated without (basal) or with insulin.
As expected, physiologic insulin stimulation resulted in increased ac-
tive cell surface GLUT4 content compared to basal unstimulated
healthy myocytes, while there was no difference in cell surface
GLUT12 compared to basal condition (Fig. 3A). To further conﬁrm
the lack of regulation of GLUT12 by insulin, we also performed the
biotinylation assay in the isolated heart perfused with or without in-
sulin (Fig. 3B). Similarly, physiologic insulin stimulation increased ac-
tive cell surface GLUT-4, but not -12, content in the healthy
myocardium (Fig. 3B). We further observed that diabetes impaired
insulin-stimulated GLUT4 translocation to the cell surface, while
there was no difference in cell surface GLUT12 compared to basal con-
dition in the diabetic myocardium (Fig. 3A). These results using the
progressive biotinylation methodology were also further conﬁrmed
by immunoﬂuorescent confocal microscopy such that, while both
GLUT4 (Fig. 4A) and GLUT12 (Fig. 4C) were associated with cytosol,
peripherals and T-tubular-like structures in healthy, noninsulin-
stimulated myocytes, physiologic insulin stimulation caused signiﬁ-
cant translocation of GLUT4 (Fig. 4B), but not GLUT12 (Fig. 4D) to
cell peripherals.
3.3. Cardiac GLUTs and whole-body glucose homeostasis
We then investigated the potential contribution of GLUT-4 and -12
to whole-body glucose homeostasis under physiological and patho-
logical conditions. As expected, our model of streptozotocin-induced
type 1 diabetes resulted in sustained hyperglycemia from 1 week
after injection until the end of the study (Fig. 5A). Linear regression
analysis of active basal cell surface GLUT content (independent var-
iable) in the isolated perfused heart and venous blood [glucose]
(dependent variable) shows a signiﬁcant negative correlation be-
tween active cell surface GLUT4 and blood [glucose] in the healthy
and diabetic myocardium (P=0.007, Rsqr=0.463; Fig. 5B). Con-
versely, there was a signiﬁcant positive correlation between active
cell surface GLUT12 and blood [glucose] in these mice (P=0.045,
Rsqr=0.317; Fig. 5C). There was no signiﬁcant correlation be-
tween active cell surface GLUT-4 and -12 (P=0.62, Rsqr=0.018,
data not shown).4. Discussion
Diabetes imposes a considerable medical, economic and social
burden on societies and is quickly becoming a worldwide health crisis
that requires urgent action. Despite intensive research (primarily in
skeletal muscle and adipose tissue), the pathogenic cause of altered
glucose transport observed during diabetes remains elusive, and the
role of the more newly discovered GLUT12 isoform has not been stud-
ied in the diabetic myocardium. Using a progressive biotinylation
photolabeling technique uniquely applied to GLUT12 in both the in-
tact perfused heart and isolated myocytes, we demonstrated that
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Fig. 3. Insulin stimulation increases cell surface GLUT-4, but not -12, in the heart under
physiological conditions. A) Healthy cardiac myocytes were incubated for 20 min
without (basal) and with insulin (100 μU/ml) prior to the cell-surface biotinylation
assay. Top panel: Western blot of photolabeled isolated cardiac myocytes. Bottom
panel: Mean±SE of active cell surface cardiac GLUT protein (expressed relative to
basal values; n=6/group). L: labeled fraction (i.e., cell surface pool); UL: unlabeled
fraction (i.e., intracellular pool). # Pb0.05 vs. basal values. B) Diabetes induces alter-
ation in insulin-stimulated GLUT-4, but not -12, translocation in the heart. Isolated in-
tact hearts from healthy (Con) and type 1 diabetic (Dx) mice were perfused with or
without insulin (at physiologic concentration, 100 μU/ml, for 35 min) before
photolabeling with bio-LC-ATB-BGPA. Top panel: Western blot of photolabeled myo-
cardium. Bottom panel: Mean±SE of active cell surface cardiac GLUT protein (i.e.,
expressed relative to basal values; n=4–5/group). There is no signiﬁcant difference
in the unlabeled GLUT fraction for any of the groups (with and without insulin stimu-
lation, data not shown). L: labeled fraction (i.e., cell surface pool); UL: unlabeled frac-
tion (i.e., intracellular pool). #Pb0.05 vs. basal values.
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face of GLUT-4, but not -12, under physiological conditions. We fur-
ther showed that basal active cell surface GLUT12 content was
increased in the diabetic myocardium, potentially as a compensatory
mechanism for the observed downregulation of active GLUT4, in the
face of persistent hyperglycemia. Overall, our data suggest that
GLUT12 in the heart functions as a basal GLUT primarily located at
the cell surface.
The discovery over 15 years ago that GLUT4 knockout mice do not
develop hyperglycemia [5] and still demonstrate modest insulin-
stimulated glucose uptake in skeletal muscle [18] clearly suggestedthat other GLUT isoforms may play a key role in the regulation of glu-
cose transport. However, data on GLUT12, one of the more newly dis-
covered GLUT isoforms, still remains extremely scarce. While it has
been suggested that GLUT12 is primarily located intracellularly in
some tissues [9,19] and could be a novel second insulin-sensitive glu-
cose transporter [7,8], the regulation and functional signiﬁcance of
GLUT12 in the heart, one of the main organs to utilize glucose, is un-
known. Surprisingly, our data demonstrates that the proportion of
GLUT located at the cell surface and intracellularly exhibits starkly op-
posite regulation for GLUT-4 and -12. Consistent with its well-
accepted function as a translocatable GLUT primarily located intracel-
lularly under basal conditions [20], in the present study, the amount
of basal active GLUT4 at the cell surface was 31% in the healthy myo-
cardium. Our novel biotinylation results are similar to those obtained
by membrane fractionation, suggesting that 28% of basal GLUT4 is
membrane-associated in the healthy heart [21]. By contrast, our re-
sults show that cell surface GLUT12 contributes to the majority of
myocardial GLUT12 protein in the healthy and diabetic state,
suggesting that in the heart, GLUT12 functions mainly as a basal cell
surface glucose transporter. Furthermore, using both biotinylation
and confocal imaging techniques, the present study provides novel
evidence that, in contrast to GLUT4, there is no measurable increase
in cell surface GLUT12 following physiological insulin stimulation in
healthy myocardium, suggesting that insulin-stimulated GLUT12
translocation is not a major regulatory process in the heart. This is
contrary to the limited research in skeletal muscle suggesting that
GLUT12 translocates to the healthy sarcolemma after insulin stimula-
tion [7,11]. In healthy humans, in vivo insulin stimulation increased
GLUT12 protein content measured by membrane fractionation [7].
However, it must be noted that many studies investigating GLUT traf-
ﬁcking utilize techniques, which cannot differentiate active GLUTs at
the cell surface from inactive GLUTs (i.e., before membrane docking
and fusion) [12,15]. Therefore, in the present study, we performed a
cell surface biotinylation assay in both the intact perfused hearts
and isolated cardiac myocytes, using an impermeable bis-mannose
compound, which is speciﬁc for GLUTs and only labels those that
are accessible (active) at the cell surface. Complementary to the con-
ﬁrmatory confocal imaging analysis performed, this biotinylation
technique allows us to reliably quantify the proportion of active
GLUT at the myocardial cell surface, and to our knowledge we are
the ﬁrst to successfully apply this methodology to GLUT12.
Overall, it appears that GLUT12 function and regulation is different
in the heart compared with other insulin-sensitive tissues (i.e., skele-
tal muscle and adipose). Interestingly, our ﬁndings are consistent
with and further build upon a recent study performed in transgenic
mice overexpressing GLUT12 [8]. Although this study demonstrated
increased whole body glucose tolerance and enhanced insulin-
stimulated (but not basal) glucose uptake in insulin-sensitive tissues
of transgenic mice overexpressing GLUT12, the enhanced glucose
clearance with GLUT12 overexpression showed tissue speciﬁcity: In
the heart, insulin stimulation resulted in a 140 and 144.5% increase
in glucose clearance compared with basal conditions in wild type
and transgenic mice, respectively. By contrast, the increase in insulin
stimulated glucose clearance was markedly higher in all other periph-
eral tissues studied (an increase of 1090 and 2380% in EDL, 600 and
1200% in soleus, and 150 and 290% in fat, was reported in wildtype
and transgenic mice, respectively) [8]. These previous ﬁndings are es-
pecially interesting in light of the ~2-fold higher degree of GLUT12
protein overexpression in the heart compared to all other tissues
studied [8]. In addition, insulin also does not stimulate acute translo-
cation of GLUT12 in MCF-7 cancer cells [9]. Taken together, the present
and previous studies provide new evidence that, while GLUT12 contrib-
utes to whole body insulin sensitivity and may function as a second
insulin-regulatable transporter in skeletal muscle and adipose tissue, its
primary role in the heart appears to be as a basal non-translocatable
GLUT associated with the cell surface. While a cause for the discrepancy
Fig. 4. Insulin stimulation causes signiﬁcant translocation of GLUT4, but not GLUT12, to cell peripherals, as visualized by confocal laser scanning microscopy. Adult rat cardiac
myocytes were incubated without (A, C) or with insulin (B, D, 100 μU/ml) for 30 min prior to immunoﬂuorescent staining. Results were analyzed from three independent exper-
iments with at least 70 cells/treatment. Scale bar: 10 μm.
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readily apparent, a similar ﬁnding has been reported for another GLUT
isoform, GLUT1. GLUT1 has been referred to as another basal transporter
in the heart (known to be primarily associated with the plasma mem-
brane and to exhibit minimal insulin-stimulated translocation) [21,24],
while it has been shown to translocate to the adipocyte plasma mem-
brane upon insulin stimulation [25]. Therefore, such discrepancies may
reﬂect tissue speciﬁc regulation of GLUTs. In addition, since contraction-
inducedGLUT4 translocation could be amajormechanism regulating car-
diac glucose transport, further studies are required to investigate the po-
tential role of calcium/contraction pathways on the regulation of GLUT12
in the heart [1].
Although there is a continued lack of understanding of the patho-
genic mechanisms underlying diabetes and its cardiac complications,
several studies have investigated the pathogenic role of GLUT4 [1]. In
the present, we used a type 1 diabetic model in order to best investi-
gate insulin-stimulated GLUT12 regulation, since the confounding ef-
fect of endogenous insulin is down-regulated to null. This animal
model is also highly relevant to type 2 (non-insulin dependent) dia-
betes. In particular, streptozotocin-induced type 1 diabetes also re-
sults in peripheral insulin resistance and, in particular, impaired
cardiac insulin signaling and GLUT4 translocation [22,23]. Further-
more, while there is initially insulin resistance in type 2 diabetes, as
the disease progresses there is also insulin deﬁciency secondary to
the exhaustion of pancreatic beta cells. Consistent with previous re-
ports using membrane fractionation of the heart [26,27], we observed
a decreased cell surface GLUT4 content in both the intact perfused
heart and isolated myocytes in our diabetic model. In addition, we
also observed impairment in insulin-stimulated GLUT4 translocation,
which reﬂects the fact that type 1 diabetes also results in peripheral
insulin resistance and impaired cardiac insulin signaling [22,23]. Sim-
ilarly, GLUT12 could be a major player in the pathogenesis of altered
glucose transport during insulin resistance and diabetes; however, its
role during these pathophysiological states, especially in the heart,remains unclear. Our results demonstrated a 2.5 fold increase in
basal cell surface GLUT12 content in the diabetic heart, which was
an inverse response to that of GLUT4. By contrast, the limited litera-
ture focusing on other insulin-sensitive tissues has not shown any dif-
ferences in GLUT12, either in skeletal muscle mRNA expression from
human type II diabetics [28], or in protein expression of skeletal mus-
cle and adipose tissue in a large animal model of naturally-occurring
compensated insulin resistance [11,12]. However it should be noted
that, in contrast to the type 1 diabetic model employed in the present
study, the insulin resistant/diabetic subjects from these previous
studies did not exhibit signiﬁcant hyperglycemia [11,12,28]. There-
fore, although the mechanisms inducing this apparent upregulation
in primarily basal GLUTs (e.g., GLUT12) is not well-elucidated, they
broadly appear to be a consequence of the systemic disturbances in
glucose metabolism [1,29].
Since the heart is one of the main organs to utilize glucose [1], we
investigated the relationship between active cell surface cardiac
GLUTs and whole-body glucose homeostasis. It is well established
that altering cell surface GLUT4 content in insulin-sensitive tissues af-
fects peripheral blood [glucose] [4–6], and cell surface GLUT4 content
of skeletal muscle and glucose transport are known to be closely asso-
ciated in the healthy and diabetic state [30,31]. The present data pro-
vides further evidence that cardiac GLUT4 plays a role in regulating
whole body glucose homeostasis, such that active cell surface
GLUT4 was negatively correlated with blood [glucose] in healthy
and diabetic mice. By contrast, we demonstrated a signiﬁcant positive
correlation between active cell surface GLUT12 and blood [glucose] in
the healthy and diabetic heart, suggesting that a compensatory in-
crease in the basal GLUT12 could occur secondary to impaired
insulin-mediated GLUT4 signaling and concomitant dysregulation of
glucose metabolism. Indeed, certain pathophysiological states
known to decrease cardiac GLUT4 content such as cardiac ischemia
and heart failure have concomitantly been shown to result in in-
creased basal GLUT1 [1,32,33] and GLUT12 [10]. Type 1 diabetes
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Fig. 5. Scatterplot and linear regressions of myocardial cell surface GLUT content
(independent variable) and venous blood [glucose] (dependent variable) show signiﬁ-
cant correlations between active cell surface GLUT and blood [glucose] in the healthy
and diabetic myocardium. A) Type 1 diabetes results in sustained hyperglycemia.
Mean±SE venous fasting blood glucose concentration in healthy (Con) and diabetic
(Dx) mice obtained at baseline (0) and up to 56 days after ﬁnal streptozotocin injection
(n=7–10/group), #Pb0.05 vs. baseline (0). B) In vivo blood [glucose] was negatively cor-
related with active basal cell surface GLUT4 in the healthy and diabetic myocardium at
8 weeks post induction of diabetes (n=4–10/group). P=0.007, Rsqr=0.463. [glu-
cose]=433.724–(316.792×GLUT4). C) By contrast, blood [glucose] was positively corre-
lated with active basal cell surface GLUT12 in the healthy and diabetic myocardium (n=
4–10/group). P=0.045, Rsqr=0.317. [glucose]=153.244+(42.349×GLUT12).
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skeletal muscle [29], and presently we further demonstrate similar
ﬁndings with GLUT-4 and -12 in cardiac muscle. Taken together,
these results suggest that the functional effect of cardiac GLUT12
upregulation is of minor consequence to overall glucose metabolism.
However, further studies will be required to establish if the observed
GLUT12 upregulation is an adaptive response with at least some func-
tional and beneﬁcial consequence for preserving myocardial glucose
transport. In addition, further studies will be required to evaluate
the functional signiﬁcance of GLUT12 in comparison with other
established basal GLUTs (e.g., GLUT-1 and -5). Indeed, given the prev-
alence of associated cardiovascular co-morbidities and lack of effec-
tive insulin sensitizing therapy for diabetic patients, the non-insulinstimulated GLUTs represent an intriguing therapeutic avenue. For ex-
ample, while research has shown that exercise training during diabe-
tes has limited beneﬁt to restore cardiac GLUT4 content [27], results
in healthy human skeletal muscle suggest that exercise-induced in-
creases in GLUT content, which is at least 2-fold greater for GLUT12
than any of the other isoforms studied including GLUT4 [34]. Thus
further investigation into the regulation of the class III of GLUTs is
still needed, particularly with respect to their overall contribution to
cardiac glucose uptake in healthy and pathophysiological states.
5. Conclusions
In summary, using a cell surface biotinylation assay in both the
intact perfused hearts and isolated cardiac myocytes as well as immuno-
ﬂuorescent confocal microscopy, we demonstrated that physiologic
insulin-stimulation does not signiﬁcantly regulate myocardial GLUT12
translocation to the cell surface. In addition, active cell surface GLUT12
was increased in the diabeticmyocardium, potentially as a compensatory
mechanism for the observed downregulation of active GLUT4. Collective-
ly our data suggest that, in contrast to GLUT4, GLUT12 appears to function
as a basal GLUT located primarily at the cell surface in the heart.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.09.013.
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